Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder

Summary

AstraZeneca's Ultomiris failed in a rare blood disorder indication, resulting in a gain for competitor Omeros. The failure removes a competing treatment option in the rare blood disorder space.